{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:41:21Z","timestamp":1790710881631,"version":"4.1.0"},"reference-count":167,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["IF130829"],"award-info":[{"award-number":["IF130829"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,4,29]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Glaucoma is a progressive optic neuropathy causing visual impairment and Retinal Ganglionic Cells (RGCs) death gradually posing a need for neuroprotective strategies to minimize the loss of RGCs and visual field. It is recognized as a multifactorial disease, Intraocular Pressure (IOP) being the foremost risk factor. ROCK inhibitors have been probed for various possible indications, such as myocardial ischemia, hypertension, kidney diseases. Their role in neuroprotection and neuronal regeneration has been suggested to be of value in the treatment of neurological diseases, like spinal-cord injury, Alzheimer\u2019s disease and multiple sclerosis but recently Rho-associated Kinase inhibitors have been recognized as potential antiglaucoma agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Synthesis:<\/jats:title>\n                    <jats:p>Rho-Kinase is a serine\/threonine kinase with a kinase domain which is constitutively active and is involved in the regulation of smooth muscle contraction and stress fibre formation. Two isoforms of Rho-Kinase, ROCK-I (ROCK \u03b2) and ROCK-II (ROCK \u03b1) have been identified. ROCK II plays a pathophysiological role in glaucoma and hence the inhibitors of ROCK may be beneficial to ameliorate the vision loss. These inhibitors decrease the intraocular pressure in the glaucomatous eye by increasing the aqueous humour outflow through the trabecular meshwork pathway. They also act as anti-scarring agents and hence prevent post-operative scarring after the glaucoma filtration surgery. Their major role involves axon regeneration by increasing the optic nerve blood flow which may be useful in treating the damaged optic neurons. These drugs act directly on the neurons in the central visual pathway, interrupting the RGC apoptosis and therefore serve as a novel pharmacological approach for glaucoma neuroprotection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on the results of high-throughput screening, several Rho kinase inhibitors have been designed and developed comprising of diverse scaffolds exhibiting Rho kinase inhibitory activity from micromolar to subnanomolar ranges. This diversity in the scaffolds with inhibitory potential against the kinase and their SAR development will be intricated in the present review. Ripasudil is the only Rho kinase inhibitor marketed to date for the treatment of glaucoma. Another ROCK inhibitor AR-13324 has recently passed the clinical trials whereas AMA0076, K115, PG324, Y39983 and RKI-983 are still under trials. In view of this, a detailed and updated account of ROCK II inhibitors as the next generation therapeutic agents for glaucoma will be discussed in this review.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867325666181031102829","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T07:58:46Z","timestamp":1540972726000},"page":"2222-2256","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility"],"prefix":"10.2174","volume":"27","author":[{"given":"Vasudha","family":"Abbhi","sequence":"first","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Study (UGCCAS), Panjab University, Chandigarh 160014, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Piplani","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Study (UGCCAS), Panjab University, Chandigarh 160014, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/NOR.0b013e31824196a8","volume":"31","author":"Turkoski B.B.","year":"2012","unstructured":"Turkoski B.B.; Glaucoma and glaucoma medications. Orthop Nurs 2012,31(1),37-41","journal-title":"Orthop Nurs"},{"key":"ref=2","first-page":"667","volume":"6","author":"Kulkarni U.","year":"2012","unstructured":"Kulkarni U.; Early detection of primary open angle glaucoma: is it happening? J Clin Diagn Res 2012,6,667-670","journal-title":"J Clin Diagn Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Tham Y.C.","year":"2014","unstructured":"Tham Y.C.; Li X.; Wong T.Y.; Quigley H.A.; Aung T.; Cheng C.Y.; Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014,121(11),2081-2090","journal-title":"Ophthalmology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/ICU.0b013e3280895aea","volume":"18","author":"Gupta N.","year":"2007","unstructured":"Gupta N.; Y\u00fccel Y.H.; Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol 2007,18(2),110-114","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1385\/MN:26:1:045","volume":"26","author":"Wax M.B.","year":"2002","unstructured":"Wax M.B.; Tezel G.; Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol 2002,26(1),45-55","journal-title":"Mol Neurobiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"278-287","DOI":"10.3129\/can j ophthalmol.i07-036","volume":"42","author":"Nickells R.W.","year":"2007","unstructured":"Nickells R.W.; From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol 2007,42(2),278-287","journal-title":"Can J Ophthalmol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phrs.2012.03.002","volume":"66","author":"Pascale A.","year":"2012","unstructured":"Pascale A.; Drago F.; Govoni S.; Protecting the retinal neurons from glaucoma: lowering ocular pressure is not enough. Pharmacol Res 2012,66(1),19-32","journal-title":"Pharmacol Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.survophthal.2008.08.006","volume":"53","author":"Coleman A.L.","year":"2008","unstructured":"Coleman A.L.; Miglior S.; Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008,53(Suppl. 1),S3-S10","journal-title":"Surv Ophthalmol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(99)04240-3","volume":"354","author":"Coleman A.L.","year":"1999","unstructured":"Coleman A.L.; Glaucoma. Lancet 1999,354(9192),1803-1810","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/0301-4738.53049","volume":"57","author":"Agarwal R.","year":"2009","unstructured":"Agarwal R.; Gupta S.K.; Agarwal P.; Saxena R.; Agrawal S.S.; Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol 2009,57(4),257-266","journal-title":"Indian J Ophthalmol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"Weinreb R.N.","year":"2014","unstructured":"Weinreb R.N.; Aung T.; Medeiros F.A.; The pathophysiology and treatment of glaucoma: a review. JAMA 2014,311(18),1901-1911","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.freeradbiomed.2008.04.026","volume":"45","author":"Aslan M.","year":"2008","unstructured":"Aslan M.; Cort A.; Yucel I.; Oxidative and nitrative stress markers in glaucoma. Free Radic Biol Med 2008,45(4),367-376","journal-title":"Free Radic Biol Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1111\/aos.12298","volume":"92","author":"Costa V.P.","year":"2014","unstructured":"Costa V.P.; Harris A.; Anderson D.; Stodtmeister R.; Cremasco F.; Kergoat H.; Lovasik J.; Stalmans I.; Zeitz O.; Lanzl I.; Gugleta K.; Schmetterer L.; Ocular perfusion pressure in glaucoma. Acta Ophthalmol 2014,92(4),e252-e266","journal-title":"Acta Ophthalmol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/j.survophthal.2007.08.013","volume":"52","author":"Mozaffarieh M.","year":"2007","unstructured":"Mozaffarieh M.; Flammer J.; Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol 2007,52(Suppl. 2),S174-S179","journal-title":"Surv Ophthalmol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2010.12.036","volume":"176","author":"Crish S.D.","year":"2011","unstructured":"Crish S.D.; Calkins D.J.; Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience 2011,176,1-11","journal-title":"Neuroscience"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1021\/jm901147e","volume":"52","author":"Vieth M.","year":"2009","unstructured":"Vieth M.; Erickson J.; Wang J.; Webster Y.; Mader M.; Higgs R.; Watson I.; Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem 2009,52(20),6456-6466","journal-title":"J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1021\/jm020427b","volume":"46","author":"McGovern S.L.","year":"2003","unstructured":"McGovern S.L.; Shoichet B.K.; Kinase inhibitors: not just for kinases anymore. J Med Chem 2003,46(8),1478-1483","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbapap.2005.06.015","volume":"1754","author":"Tamura M.","year":"2005","unstructured":"Tamura M.; Nakao H.; Yoshizaki H.; Shiratsuchi M.; Shigyo H.; Yamada H.; Ozawa T.; Totsuka J.; Hidaka H.; Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005,1754(1-2),245-252","journal-title":"Biochim Biophys Acta"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/excr.2000.5046","volume":"261","author":"Amano M.","year":"2000","unstructured":"Amano M.; Fukata Y.; Kaibuchi K.; Regulation and functions of Rho-associated kinase. Exp Cell Res 2000,261(1),44-51","journal-title":"Exp Cell Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ceb.2008.01.002","volume":"20","author":"Olson M.F.","year":"2008","unstructured":"Olson M.F.; Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008,20(2),242-248","journal-title":"Curr Opin Cell Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/j.1460-2075.1996.tb00574.x","volume":"15","author":"Matsui T.","year":"1996","unstructured":"Matsui T.; Amano M.; Yamamoto T.; Chihara K.; Nakafuku M.; Ito M.; Nakano T.; Okawa K.; Iwamatsu A.; Kaibuchi K.; Rho-associated kinase, a novel serine\/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996,15(9),2208-2216","journal-title":"EMBO J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2174\/156802609789044452","volume":"9","author":"LoGrasso P.V.","year":"2009","unstructured":"LoGrasso P.V.; Feng Y.; Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009,9(8),704-723","journal-title":"Curr Top Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FJC.0b013e318070d1bd","volume":"50","author":"Liao J.K.","year":"2007","unstructured":"Liao J.K.; Seto M.; Noma K.; Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007,50(1),17-24","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","volume":"62","author":"Honjo M.","year":"2018","unstructured":"Honjo M.; Tanihara H.; Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol 2018,62(2),109-126","journal-title":"Jpn J Ophthalmol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","volume":"37","author":"Inoue T.","year":"2013","unstructured":"Inoue T.; Tanihara H.; Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 2013,37,1-12","journal-title":"Prog Retin Eye Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/jps.20285","volume":"94","author":"Nakajima E.","year":"2005","unstructured":"Nakajima E.; Nakajima T.; Minagawa Y.; Shearer T.R.; Azuma M.; Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005,94(4),701-708","journal-title":"J Pharm Sci"},{"key":"ref=27","first-page":"1029","volume":"42","author":"Rao P.V.","year":"2001","unstructured":"Rao P.V.; Deng P.F.; Kumar J.; Epstein D.L.; Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001,42(5),1029-1037","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.exer.2007.10.018","volume":"86","author":"Lu Z.","year":"2008","unstructured":"Lu Z.; Overby D.R.; Scott P.A.; Freddo T.F.; Gong H.; The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res 2008,86(2),271-281","journal-title":"Exp Eye Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/bjo.2010.194571","volume":"95","author":"Okumura N.","year":"2011","unstructured":"Okumura N.; Koizumi N.; Ueno M.; Sakamoto Y.; Takahashi H.; Hirata K.; Torii R.; Hamuro J.; Kinoshita S.; Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol 2011,95(7),1006-1009","journal-title":"Br J Ophthalmol"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2646904","volume":"2017","author":"Okumura N.","year":"2017","unstructured":"Okumura N.; Kinoshita S.; Koizumi N.; Application of rho kinase inhibitors for the treatment of corneal endothelial diseases. J Ophthalmol 2017,2017","journal-title":"J Ophthalmol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"438e","DOI":"10.1097\/PRS.0b013e31822b7352","volume":"128","author":"Bond J.E.","year":"2011","unstructured":"Bond J.E.; Kokosis G.; Ren L.; Selim M.A.; Bergeron A.; Levinson H.; Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase. Plast Reconstr Surg 2011,128(5),438e-450e","journal-title":"Plast Reconstr Surg"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2013.2100","volume":"43","author":"Wang J.","year":"2013","unstructured":"Wang J.; Liu X.; Zhong Y.; Rho\/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol 2013,43(5),1357-1367","journal-title":"Int J Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.brainres.2007.04.013","volume":"1154","author":"Yamashita K.","year":"2007","unstructured":"Yamashita K.; Kotani Y.; Nakajima Y.; Shimazawa M.; Yoshimura S.; Nakashima S.; Iwama T.; Hara H.; Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007,1154,215-224","journal-title":"Brain Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.exer.2016.07.006","volume":"158","author":"Shaw P.X.","year":"2017","unstructured":"Shaw P.X.; Sang A.; Wang Y.; Ho D.; Douglas C.; Dia L.; Goldberg J.L.; Topical administration of a Rock\/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury. Exp Eye Res 2017,158,33-42","journal-title":"Exp Eye Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.4103\/1673-5374.172311","volume":"10","author":"Hove I.V.","year":"2015","unstructured":"Hove I.V.; Lefevere E.; Moons L.; ROCK inhibition as a novel potential strategy for axonal regeneration in optic neuropathies. Neural Regen Res 2015,10(12),1949-1950","journal-title":"Neural Regen Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","volume":"131","author":"Van de Velde S.","year":"2015","unstructured":"Van de Velde S.; De Groef L.; Stalmans I.; Moons L.; Van Hove I.; Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. Prog Neurobiol 2015,131,105-119","journal-title":"Prog Neurobiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.str.2003.11.002","volume":"11","author":"Breitenlechner C.","year":"2003","unstructured":"Breitenlechner C.; Gassel M.; Hidaka H.; Kinzel V.; Huber R.; Engh R.A.; Bossemeyer D.; Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 2003,11(12),1595-1607","journal-title":"Structure"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.drudis.2010.06.011","volume":"15","author":"Dong M.","year":"2010","unstructured":"Dong M.; Yan B.P.; Liao J.K.; Lam Y.Y.; Yip G.W.K.; Yu C.M.; Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010,15(15-16),622-629","journal-title":"Drug Discov Today"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ejmech.2013.10.048","volume":"70","author":"Guan R.","year":"2013","unstructured":"Guan R.; Xu X.; Chen M.; Hu H.; Ge H.; Wen S.; Zhou S.; Pi R.; Advances in the studies of roles of Rho\/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem 2013,70,613-622","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ph3072111","volume":"3","author":"Dhalla N.S.","year":"2010","unstructured":"Dhalla N.S.; M\u00fcller A.L.; Protein kinases as drug development targets for heart disease therapy. Pharmaceuticals (Basel) 2010,3(7),2111-2145","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1161\/01.STR.0000181077.84981.11","volume":"36","author":"Rikitake Y.","year":"2005","unstructured":"Rikitake Y.; Kim H.H.; Huang Z.; Seto M.; Yano K.; Asano T.; Moskowitz M.A.; Liao J.K.; Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005,36(10),2251-2257","journal-title":"Stroke"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.bmc.2004.02.025","volume":"12","author":"Takami A.","year":"2004","unstructured":"Takami A.; Iwakubo M.; Okada Y.; Kawata T.; Odai H.; Takahashi N.; Shindo K.; Kimura K.; Tagami Y.; Miyake M.; Fukushima K.; Inagaki M.; Amano M.; Kaibuchi K.; Iijima H.; Design and synthesis of Rho kinase inhibitors (I). Bioorg Med Chem 2004,12(9),2115-2137","journal-title":"Bioorg Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1167\/iovs.10-6241","volume":"52","author":"Ramachandran C.","year":"2011","unstructured":"Ramachandran C.; Patil R.V.; Sharif N.A.; Srinivas S.P.; Effect of elevated intracellular cAMP levels on actomyosin contraction in bovine trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011,52(3),1474-1485","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.drudis.2013.09.010","volume":"18","author":"Pan P.","year":"2013","unstructured":"Pan P.; Shen M.; Yu H.; Li Y.; Li D.; Hou T.; Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today 2013,18(23-24),1323-1333","journal-title":"Drug Discov Today"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00109-002-0370-2","volume":"80","author":"Wettschureck N.","year":"2002","unstructured":"Wettschureck N.; Offermanns S.; Rho\/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl) 2002,80(10),629-638","journal-title":"J Mol Med (Berl)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrm1128","volume":"4","author":"Riento K.","year":"2003","unstructured":"Riento K.; Ridley A.J.; Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003,4(6),446-456","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1039\/c3mb00016h","volume":"9","author":"Shen M.","year":"2013","unstructured":"Shen M.; Yu H.; Li Y.; Li P.; Pan P.; Zhou S.; Zhang L.; Li S.; Lee S.M.; Hou T.; Discovery of Rho-kinase inhibitors by docking-based virtual screening. Mol Biosyst 2013,9(6),1511-1521","journal-title":"Mol Biosyst"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"29846","DOI":"10.4161\/sgtp.29846","volume":"5e","author":"Julian L.","year":"2014","unstructured":"Julian L.; Olson M.F.; Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 2014,5e,29846","journal-title":"Small GTPases"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1146\/annurev.biochem.68.1.459","volume":"68","author":"Kaibuchi K.","year":"1999","unstructured":"Kaibuchi K.; Kuroda S.; Amano M.; Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 1999,68,459-486","journal-title":"Annu Rev Biochem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.drudis.2010.02.007","volume":"15","author":"Dahlmann-Noor A.H.","year":"2010","unstructured":"Dahlmann-Noor A.H.; Vijay S.; Limb G.A.; Khaw P.T.; Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today 2010,15(7-8),287-299","journal-title":"Drug Discov Today"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"8948","DOI":"10.1021\/bi0258243","volume":"41","author":"Trauger J.W.","year":"2002","unstructured":"Trauger J.W.; Lin F.F.; Turner M.S.; Stephens J.; LoGrasso P.V.; Kinetic mechanism for human Rho-Kinase II (ROCK-II). Biochemistry 2002,41(28),8948-8953","journal-title":"Biochemistry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2004.05.070","volume":"1018","author":"Kitaoka Y.","year":"2004","unstructured":"Kitaoka Y.; Kitaoka Y.; Kumai T.; Lam T.T.; Kuribayashi K.; Isenoumi K.; Munemasa Y.; Motoki M.; Kobayashi S.; Ueno S.; Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res 2004,1018(1),111-118","journal-title":"Brain Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1367-5931(99)80067-2","volume":"3","author":"Cohen P.","year":"1999","unstructured":"Cohen P.; The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 1999,3(4),459-465","journal-title":"Curr Opin Chem Biol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.aal5060","volume":"356","author":"Laha B.","year":"2017","unstructured":"Laha B.; Stafford B.K.; Huberman A.D.; Regenerating optic pathways from the eye to the brain. Science 2017,356(6342),1031-1034","journal-title":"Science"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1167\/iovs.11-8018","volume":"53","author":"Kameda T.","year":"2012","unstructured":"Kameda T.; Inoue T.; Inatani M.; Fujimoto T.; Honjo M.; Kasaoka N.; Inoue-Mochita M.; Yoshimura N.; Tanihara H.; The effect of Rho-associated protein kinase inhibitor on monkey Schlemm\u2019s canal endothelial cells. Invest Ophthalmol Vis Sci 2012,53(6),3092-3103","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.exer.2010.08.005","volume":"93","author":"Morrison J.C.","year":"2011","unstructured":"Morrison J.C.; Cepurna Ying Guo W.O.; Johnson E.C.; Pathophysiology of human glaucomatous optic nerve damage: insights from rodent models of glaucoma. Exp Eye Res 2011,93(2),156-164","journal-title":"Exp Eye Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3129\/i07-051","volume":"42","author":"Gupta N.","year":"2007","unstructured":"Gupta N.; Y\u00fccel Y.H.; Should we treat the brain in glaucoma? Can J Ophthalmol 2007,42(3),409-413","journal-title":"Can J Ophthalmol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd1719","volume":"4","author":"Mueller B.K.","year":"2005","unstructured":"Mueller B.K.; Mack H.; Teusch N.; Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005,4(5),387-398","journal-title":"Nat Rev Drug Discov"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.RES.87.3.195","volume":"87","author":"Sato M.","year":"2000","unstructured":"Sato M.; Tani E.; Fujikawa H.; Kaibuchi K.; Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000,87(3),195-200","journal-title":"Circ Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1167\/iovs.15-18586","volume":"57","author":"Okumura N.","year":"2016","unstructured":"Okumura N.; Okazaki Y.; Inoue R.; Kakutani K.; Nakano S.; Kinoshita S.; Koizumi N.; Effect of the Rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci 2016,57(3),1284-1292","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10384-017-0524-y","volume":"61","author":"Ohta Y.","year":"2017","unstructured":"Ohta Y.; Takaseki S.; Yoshitomi T.; Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits. Jpn J Ophthalmol 2017,61(5),423-432","journal-title":"Jpn J Ophthalmol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5772\/26559","author":"Shahidullah M.","year":"2011","unstructured":"Shahidullah M.; Al-Malki W.H.; Delamere N.A.; Mechanism of aqueous humor secretion, its regulation and relevance to glaucoma 2011,3-32","journal-title":"Mechanism of aqueous humor secretion, its regulation and relevance to glaucoma"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2016.12.004","volume":"57","author":"Carreon T.","year":"2017","unstructured":"Carreon T.; van der Merwe E.; Fellman R.L.; Johnstone M.; Bhattacharya S.K.; Aqueous outflow - A continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res 2017,57,108-133","journal-title":"Prog Retin Eye Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1167\/iovs.15-16744","volume":"56","author":"Roy Chowdhury U.","year":"2015","unstructured":"Roy Chowdhury U.; Hann C.R.; Stamer W.D.; Fautsch M.P.; Aqueous humor outflow: dynamics and disease. Invest Ophthalmol Vis Sci 2015,56(5),2993-3003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.exer.2016.01.017","volume":"158","author":"Johnson M.","year":"2017","unstructured":"Johnson M.; McLaren J.W.; Overby D.R.; Unconventional aqueous humor outflow: A review. Exp Eye Res 2017,158,94-111","journal-title":"Exp Eye Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/IJG.0b013e318241b83c","volume":"21","author":"Goldhagen B.","year":"2012","unstructured":"Goldhagen B.; Proia A.D.; Epstein D.L.; Rao P.V.; Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma. J Glaucoma 2012,21(8),530-538","journal-title":"J Glaucoma"},{"key":"ref=67","first-page":"1877","volume":"17","author":"Ramachandran C.","year":"2011","unstructured":"Ramachandran C.; Patil R.V.; Combrink K.; Sharif N.A.; Srinivas S.P.; Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Mol Vis 2011,17,1877-1890","journal-title":"Mol Vis"},{"key":"ref=68","first-page":"619","volume":"41","author":"Tian B.","year":"2000","unstructured":"Tian B.; Geiger B.; Epstein D.L.; Kaufman P.L.; Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 2000,41(3),619-623","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.exer.2008.01.013","volume":"86","author":"Acott T.S.","year":"2008","unstructured":"Acott T.S.; Kelley M.J.; Extracellular matrix in the trabecular meshwork. Exp Eye Res 2008,86(4),543-561","journal-title":"Exp Eye Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.exer.2008.08.008","volume":"88","author":"Tian B.","year":"2009","unstructured":"Tian B.; Gabelt B.T.; Geiger B.; Kaufman P.L.; The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 2009,88(4),713-717","journal-title":"Exp Eye Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1350-9462(98)00011-1","volume":"18","author":"L\u00fctjen-Drecoll E.","year":"1999","unstructured":"L\u00fctjen-Drecoll E.; Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res 1999,18(1),91-119","journal-title":"Prog Retin Eye Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"C749","DOI":"10.1152\/ajpcell.00317.2009","volume":"298","author":"Pattabiraman P.P.","year":"2010","unstructured":"Pattabiraman P.P.; Rao P.V.; Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol 2010,298(3),C749-C763","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1586\/eop.11.65","volume":"6","author":"Mandell K.J.","year":"2011","unstructured":"Mandell K.J.; Kudelka M.R.; Wirostko B.; Rho kinase inhibitors for treatment of glaucoma. Expert Rev Ophthalmol 2011,6(6),611-622","journal-title":"Expert Rev Ophthalmol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"C1057","DOI":"10.1152\/ajpcell.00481.2007","volume":"295","author":"Zhang M.","year":"2008","unstructured":"Zhang M.; Maddala R.; Rao P.V.; Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol 2008,295(5),C1057-C1070","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=75","first-page":"137","volume":"42","author":"Honjo M.","year":"2001","unstructured":"Honjo M.; Tanihara H.; Inatani M.; Kido N.; Sawamura T.; Yue B.Y.; Narumiya S.; Honda Y.; Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001,42(1),137-144","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.exer.2005.07.006","volume":"82","author":"Koga T.","year":"2006","unstructured":"Koga T.; Koga T.; Awai M.; Tsutsui J.; Yue B.Y.; Tanihara H.; Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res 2006,82(3),362-370","journal-title":"Exp Eye Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/archopht.119.8.1171","volume":"119","author":"Honjo M.","year":"2001","unstructured":"Honjo M.; Inatani M.; Kido N.; Sawamura T.; Yue B.Y.; Honda Y.; Tanihara H.; Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 2001,119(8),1171-1178","journal-title":"Arch Ophthalmol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"Tokushige H.","year":"2007","unstructured":"Tokushige H.; Inatani M.; Nemoto S.; Sakaki H.; Katayama K.; Uehata M.; Tanihara H.; Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007,48(7),3216-3222","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","volume":"152","author":"Williams R.D.","year":"2011","unstructured":"Williams R.D.; Novack G.D.; van Haarlem T.; Kopczynski C.; Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol AR-12286 Phase 2A Study Group2011,152(5),834-41.e1","journal-title":"Am J Ophthalmol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1089\/jop.2008.0029","volume":"24","author":"Yu M.","year":"2008","unstructured":"Yu M.; Chen X.; Wang N.; Cai S.; Li N.; Qiu J.; Brandt C.R.; Kaufman P.L.; Liu X.; H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. J Ocul Pharmacol Ther 2008,24(4),373-379","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"Tanihara H.","year":"2013","unstructured":"Tanihara H.; Inoue T.; Yamamoto T.; Kuwayama Y.; Abe H.; Araie M.; Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol K-115 Clinical Study Group2013,156(4),731-736","journal-title":"Am J Ophthalmol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1167\/iovs.07-0878","volume":"48","author":"Honjo M.","year":"2007","unstructured":"Honjo M.; Tanihara H.; Kameda T.; Kawaji T.; Yoshimura N.; Araie M.; Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2007,48(12),5549-5557","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=83","first-page":"530","volume":"21","year":"2015","unstructured":"V. S.; Bergen, T. V.; Vandewalle, E.; Moons, L.; Stalmans, I. Modulation of Wound Healing in Glaucoma Surgery. Prog Brain Res Van de2015,21,530-538","journal-title":"Prog Brain Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00055735-200104000-00011","volume":"12","author":"Khaw P.T.","year":"2001","unstructured":"Khaw P.T.; Chang L.; Wong T.T.; Mead A.; Daniels J.T.; Cordeiro M.F.; Modulation of wound healing after glaucoma surgery. Curr Opin Ophthalmol 2001,12(2),143-148","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0161-6420(84)34277-4","volume":"91","author":"Gressel M.G.","year":"1984","unstructured":"Gressel M.G.; Parrish R.K.; Folberg R.; 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmology 1984,91(4),378-383","journal-title":"Ophthalmology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1167\/iovs.04-0820","volume":"46","author":"Wong T.T.","year":"2005","unstructured":"Wong T.T.; Mead A.L.; Khaw P.T.; Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2005,46(6),2018-2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nrm3896","volume":"15","author":"Humphrey J.D.","year":"2014","unstructured":"Humphrey J.D.; Dufresne E.R.; Schwartz M.A.; Mechanotransduction and extracellular matrix homeostasis. Nat Rev Mol Cell Biol 2014,15(12),802-812","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/261386","volume":"2013","author":"Rocha-Sousa A.","year":"2013","unstructured":"Rocha-Sousa A.; Rodrigues-Ara\u00fajo J.; Gouveia P.; Barbosa-Breda J.; Azevedo-Pinto S.; Pereira-Silva P.; Leite-Moreira A.; New therapeutic targets for intraocular pressure lowering. ISRN Ophthalmol 2013,2013","journal-title":"ISRN Ophthalmol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1167\/iovs.06-1271","volume":"48","author":"Tura A.","year":"2007","unstructured":"Tura A.; Grisanti S.; Petermeier K.; Henke-Fahle S.; The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon\u2019s capsule fibroblasts in vitro. Invest Ophthalmol Vis Sci 2007,48(5),2152-2161","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/jop.2008.0142","volume":"25","author":"Whitlock N.A.","year":"2009","unstructured":"Whitlock N.A.; Harrison B.; Mixon T.; Yu X.Q.; Wilson A.; Gerhardt B.; Eberhart D.E.; Abuin A.; Rice D.S.; Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J Ocul Pharmacol Ther 2009,25(3),187-194","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1076\/ceyr.22.6.470.5489","volume":"22","author":"Waki M.","year":"2001","unstructured":"Waki M.; Yoshida Y.; Oka T.; Azuma M.; Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001,22(6),470-474","journal-title":"Curr Eye Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"Tanihara H.","year":"2008","unstructured":"Tanihara H.; Inatani M.; Honjo M.; Tokushige H.; Azuma J.; Araie M.; Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008,126(3),309-315","journal-title":"Arch Ophthalmol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajpath.2014.10.023","volume":"185","author":"Pattabiraman P.P.","year":"2015","unstructured":"Pattabiraman P.P.; Rinkoski T.; Poeschla E.; Proia A.; Challa P.; Rao P.V.; Rho A.; RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork. Am J Pathol 2015,185(2),496-512","journal-title":"Am J Pathol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0161-6420(96)30572-1","volume":"103","author":"Siegner S.W.","year":"1996","unstructured":"Siegner S.W.; Netland P.A.; Optic disc hemorrhages and progression of glaucoma. Ophthalmology 1996,103(7),1014-1024","journal-title":"Ophthalmology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ophtha.2004.10.034","volume":"112","author":"Krupin T.","year":"2005","unstructured":"Krupin T.; Liebmann J.M.; Greenfield D.S.; Rosenberg L.F.; Ritch R.; Yang J.W.; The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology Low-Pressure Glaucoma Study Group2005,112(3),376-385","journal-title":"Ophthalmology"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/jop.2006.128","volume":"23","author":"Okamura N.","year":"2007","unstructured":"Okamura N.; Saito M.; Mori A.; Sakamoto K.; Kametaka S.; Nakahara T.; Ishii K.; Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther 2007,23(3),207-212","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10384-011-0048-9","volume":"55","author":"Watabe H.","year":"2011","unstructured":"Watabe H.; Abe S.; Yoshitomi T.; Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries. Jpn J Ophthalmol 2011,55(4),411-417","journal-title":"Jpn J Ophthalmol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1167\/iovs.10-5265","volume":"52","author":"Sugiyama T.","year":"2011","unstructured":"Sugiyama T.; Shibata M.; Kajiura S.; Okuno T.; Tonari M.; Oku H.; Ikeda T.; Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci 2011,52(1),64-69","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.exer.2015.07.008","volume":"139","author":"Nakabayashi S.","year":"2015","unstructured":"Nakabayashi S.; Kawai M.; Yoshioka T.; Song Y.S.; Tani T.; Yoshida A.; Nagaoka T.; Effect of intravitreal Rho kinase inhibitor ripasudil (K-115) on feline retinal microcirculation. Exp Eye Res 2015,139,132-135","journal-title":"Exp Eye Res"},{"key":"ref=100","first-page":"207","volume":"5","author":"Alexandrescu C.","year":"2010","unstructured":"Alexandrescu C.; Dascalu A.M.; Mitulescu C.; Panca A.; Pascu R.; Ciuluvica R.; Potop V.; Voinea L.M.; Evidence-based pathophysiology of glaucoma. Maedica (Buchar) 2010,5(3),207-213","journal-title":"Maedica (Buchar)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0079-6123(08)01127-8","volume":"173","author":"Sacc\u00e0 S.C.","year":"2008","unstructured":"Sacc\u00e0 S.C.; Izzotti A.; Oxidative stress and glaucoma: injury in the anterior segment of the eye. Prog Brain Res 2008,173,385-407","journal-title":"Prog Brain Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/OPTH.S10922","volume":"4","author":"Oshida E.","year":"2010","unstructured":"Oshida E.; Matsumoto Y.; Arai K.; Free radicals in the aqueous humor of patients with glaucoma. Clin Ophthalmol 2010,4,653-660","journal-title":"Clin Ophthalmol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.mrrev.2005.11.001","volume":"612","author":"Izzotti A.","year":"2006","unstructured":"Izzotti A.; Bagnis A.; Sacc\u00e0 S.C.; The role of oxidative stress in glaucoma. Mutat Res 2006,612(2),105-114","journal-title":"Mutat Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3109\/02713683.2011.599106","volume":"36","author":"Tokushige H.","year":"2011","unstructured":"Tokushige H.; Waki M.; Takayama Y.; Tanihara H.; Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res 2011,36(10),964-970","journal-title":"Curr Eye Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.expneurol.2007.02.002","volume":"205","author":"Sagawa H.","year":"2007","unstructured":"Sagawa H.; Terasaki H.; Nakamura M.; Ichikawa M.; Yata T.; Tokita Y.; Watanabe M.; A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol 2007,205(1),230-240","journal-title":"Exp Neurol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1523\/JNEUROSCI.3931-04.2005","volume":"25","author":"Bertrand J.","year":"2005","unstructured":"Bertrand J.; Winton M.J.; Rodriguez-Hernandez N.; Campenot R.B.; McKerracher L.; Application of Rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J Neurosci 2005,25(5),1113-1121","journal-title":"J Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1167\/iovs.13-13842","volume":"55","author":"Yamamoto K.","year":"2014","unstructured":"Yamamoto K.; Maruyama K.; Himori N.; Omodaka K.; Yokoyama Y.; Shiga Y.; Morin R.; Nakazawa T.; The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci 2014,55(11),7126-7136","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.bmc.2006.10.028","volume":"15","author":"Iwakubo M.","year":"2007","unstructured":"Iwakubo M.; Takami A.; Okada Y.; Kawata T.; Tagami Y.; Sato M.; Sugiyama T.; Fukushima K.; Taya S.; Amano M.; Kaibuchi K.; Iijima H.; Design and synthesis of rho kinase inhibitors (III). Bioorg Med Chem 2007,15(2),1022-1033","journal-title":"Bioorg Med Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/13543784.2013.840288","volume":"23","author":"Challa P.","year":"2014","unstructured":"Challa P.; Arnold J.J.; Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Investig Drugs 2014,23(1),81-95","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.bmcl.2016.03.113","volume":"26","author":"Shah S.","year":"2016","unstructured":"Shah S.; Savjani J.; A review on ROCK-II inhibitors: From molecular modelling to synthesis. Bioorg Med Chem Lett 2016,26(10),2383-2391","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.bmcl.2010.01.124","volume":"20","author":"Sessions E.H.","year":"2010","unstructured":"Sessions E.H.; Smolinski M.; Wang B.; Frackowiak B.; Chowdhury S.; Yin Y.; Chen Y.T.; Ruiz C.; Lin L.; Pocas J.; Schr\u00f6ter T.; Cameron M.D.; LoGrasso P.; Feng Y.; Bannister T.D.; The development of benzimidazoles as selective rho kinase inhibitors. Bioorg Med Chem Lett 2010,20(6),1939-1943","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1021\/acs.jmedchem.5b00683","volume":"59","author":"Feng Y.","year":"2016","unstructured":"Feng Y.; LoGrasso P.V.; Defert O.; Li R.; Rho Kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem 2016,59(6),2269-2300","journal-title":"J Med Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fnagi.2017.00094","volume":"9","author":"Roser A.E.","year":"2017","unstructured":"Roser A.E.; T\u00f6nges L.; Lingor P.; Modulation of microglial activity by Rho-kinase (ROCK) inhibition as therapeutic strategy in parkinson\u2019s disease and amyotrophic lateral sclerosis. Front Aging Neurosci 2017,9,94","journal-title":"Front Aging Neurosci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/TCRM.S2907","volume":"4","author":"Kubo T.","year":"2008","unstructured":"Kubo T.; Yamaguchi A.; Iwata N.; Yamashita T.; The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008,4(3),605-615","journal-title":"Ther Clin Risk Manag"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/OPTH.S41000","volume":"8","author":"Wang S.K.","year":"2014","unstructured":"Wang S.K.; Chang R.T.; An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol 2014,8,883-890","journal-title":"Clin Ophthalmol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"16749","DOI":"10.1038\/srep16749","volume":"5","author":"Shen M.","year":"2015","unstructured":"Shen M.; Tian S.; Pan P.; Sun H.; Li D.; Li Y.; Zhou H.; Li C.; Lee S.M.; Hou T.; Discovery of novel ROCK1 inhibitors via integrated virtual screening strategy and bioassays. Sci Rep 2015,5,16749","journal-title":"Sci Rep"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nrd2999","volume":"8","author":"Chico L.K.","year":"2009","unstructured":"Chico L.K.; Van Eldik L.J.; Watterson D.M.; Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009,8(11),892-909","journal-title":"Nat Rev Drug Discov"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.brainres.2008.01.063","volume":"1201","author":"Ichikawa M.","year":"2008","unstructured":"Ichikawa M.; Yoshida J.; Saito K.; Sagawa H.; Tokita Y.; Watanabe M.; Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats. Brain Res 2008,1201,23-33","journal-title":"Brain Res"},{"key":"ref=119","author":"Iwakubo M.","year":"2004","unstructured":"Iwakubo M.; Okada Y.; Isoquinoline Derivatives Having Kinase Inhibitory Activity and Drugs Containing the Same. WO Patent 2004024717, 2004"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","volume":"26","author":"Sturdivant J.M.","year":"2016","unstructured":"Sturdivant J.M.; Royalty S.M.; Lin C.W.; Moore L.A.; Yingling J.D.; Laethem C.L.; Sherman B.; Heintzelman G.R.; Kopczynski C.C.; deLong M.A.; Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2016,26(10),2475-2480","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"Garnock-Jones K.P.","year":"2014","unstructured":"Garnock-Jones K.P.; Ripasudil: first global approval. Drugs 2014,74(18),2211-2215","journal-title":"Drugs"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.03.008","volume":"189","author":"Koch J.C.","year":"2018","unstructured":"Koch J.C.; Tatenhorst L.; Roser A.E.; Saal K.A.; T\u00f6nges L.; Lingor P.; ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther 2018,189,1-21","journal-title":"Pharmacol Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/1475636031000093561","volume":"18","author":"Log\u00e9 C.","year":"2003","unstructured":"Log\u00e9 C.; Siomboing X.; Wallez V.; Scalbert E.; Bennejean C.; Cario-Tourmaniantz C.; Loirand G.; Gressier B.; Pacaud P.; Luyckx M.; Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil. J Enzyme Inhib Med Chem 2003,18(2),127-138","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=124","unstructured":"Double-Masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects with Glaucoma or Ocular Hypertension Aerie Pharmaceuticals[Accessed: Dec 3, 2016].","journal-title":"Double-Masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects with Glaucoma or Ocular Hypertension"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0026-895X(24)26508-1","volume":"57","author":"Ishizaki T.","year":"2000","unstructured":"Ishizaki T.; Uehata M.; Tamechika I.; Keel J.; Nonomura K.; Maekawa M.; Narumiya S.; Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000,57(5),976-983","journal-title":"Mol Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1016\/j.bmcl.2004.07.025","volume":"14","author":"Gingras K.","year":"2004","unstructured":"Gingras K.; Avedissian H.; Thouin E.; Boulanger V.; Essagian C.; McKerracher L.; Lubell W.D.; Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl)cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters. Bioorg Med Chem Lett 2004,14(19),4931-4934","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=127","author":"McKerracher L.T.E.","year":"2004","unstructured":"McKerracher L.T.E.; Lubell W.D.; 1, 4-Substituted Cyclohexane Derivatives. WO Patent 2004022541, 2004"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/1475636021000005659","volume":"17","author":"Log\u00e9 C.","year":"2002","unstructured":"Log\u00e9 C.; Wallez V.; Scalbert E.; Cario-Tourmaniantz C.; Loirand G.; Pacaud P.; Lesieur D.; Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885. J Enzyme Inhib Med Chem 2002,17(6),381-390","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.drudis.2011.07.006","volume":"16","author":"Kalyaanamoorthy S.","year":"2011","unstructured":"Kalyaanamoorthy S.; Chen Y.P.; Structure-based drug design to augment hit discovery. Drug Discov Today 2011,16(17-18),831-839","journal-title":"Drug Discov Today"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1021\/jm0609014","volume":"50","author":"Goodman K.B.","year":"2007","unstructured":"Goodman K.B.; Cui H.; Dowdell S.E.; Gaitanopoulos D.E.; Ivy R.L.; Sehon C.A.; Stavenger R.A.; Wang G.Z.; Viet A.Q.; Xu W.; Ye G.; Semus S.F.; Evans C.; Fries H.E.; Jolivette L.J.; Kirkpatrick R.B.; Dul E.; Khandekar S.S.; Yi T.; Jung D.K.; Wright L.L.; Smith G.K.; Behm D.J.; Bentley R.; Doe C.P.; Hu E.; Lee D.; Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem 2007,50(1),6-9","journal-title":"J Med Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejphar.2013.01.027","volume":"702","author":"Oh K.S.","year":"2013","unstructured":"Oh K.S.; Oh B.K.; Park C.H.; Seo H.W.; Kang N.S.; Lee J.H.; Lee J.S.; Ho Lee B.; Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). Eur J Pharmacol 2013,702(1-3),218-226","journal-title":"Eur J Pharmacol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.bmcl.2006.12.043","volume":"17","author":"Feng Y.","year":"2007","unstructured":"Feng Y.; Cameron M.D.; Frackowiak B.; Griffin E.; Lin L.; Ruiz C.; Schr\u00f6ter T.; LoGrasso P.; Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Bioorg Med Chem Lett 2007,17(8),2355-2360","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bmc.2006.09.052","volume":"15","author":"Iwakubo M.","year":"2007","unstructured":"Iwakubo M.; Takami A.; Okada Y.; Kawata T.; Tagami Y.; Ohashi H.; Sato M.; Sugiyama T.; Fukushima K.; Iijima H.; Design and synthesis of Rho kinase inhibitors (II). Bioorg Med Chem 2007,15(1),350-364","journal-title":"Bioorg Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.1021\/jm800986w","volume":"51","author":"Feng Y.","year":"2008","unstructured":"Feng Y.; Yin Y.; Weiser A.; Griffin E.; Cameron M.D.; Lin L.; Ruiz C.; Sch\u00fcrer S.C.; Inoue T.; Rao P.V.; Schr\u00f6ter T.; Lograsso P.; Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem 2008,51(21),6642-6645","journal-title":"J Med Chem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1016\/j.bmcl.2008.10.080","volume":"18","author":"Chen Y.T.","year":"2008","unstructured":"Chen Y.T.; Bannister T.D.; Weiser A.; Griffin E.; Lin L.; Ruiz C.; Cameron M.D.; Sch\u00fcrer S.; Duckett D.; Schr\u00f6ter T.; LoGrasso P.; Feng Y.; Chroman-3-amides as potent Rho kinase inhibitors. Bioorg Med Chem Lett 2008,18(24),6406-6409","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1016\/j.bmcl.2008.10.095","volume":"18","author":"Sessions E.H.","year":"2008","unstructured":"Sessions E.H.; Yin Y.; Bannister T.D.; Weiser A.; Griffin E.; Pocas J.; Cameron M.D.; Ruiz C.; Lin L.; Sch\u00fcrer S.C.; Schr\u00f6ter T.; LoGrasso P.; Feng Y.; Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg Med Chem Lett 2008,18(24),6390-6393","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.1039\/c3ra46304d","volume":"4","author":"Singla P.","year":"2014","unstructured":"Singla P.; Luxami V.; Paul K.; Benzimidazole-biologically attractive scaffold for protein kinase inhibitors. RSC Advances 2014,4,12422-12440","journal-title":"RSC Advances"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-0348-7139-6_7","volume":"37","author":"Burger A.","year":"1991","unstructured":"Burger A.; Isosterism and bioisosterism in drug design. Prog Drug Res 1991,37,287-371","journal-title":"Prog Drug Res"},{"key":"ref=139","first-page":"471","volume":"4","author":"Olesen P.H.","year":"2001","unstructured":"Olesen P.H.; The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 2001,4(4),471-478","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1016\/j.bmcl.2009.09.115","volume":"19","author":"Yin Y.","year":"2009","unstructured":"Yin Y.; Lin L.; Ruiz C.; Cameron M.D.; Pocas J.; Grant W.; Schr\u00f6ter T.; Chen W.; Duckett D.; Sch\u00fcrer S.; Lograsso P.; Feng Y.; Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors. Bioorg Med Chem Lett 2009,19(23),6686-6690","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1016\/j.bmcl.2010.06.067","volume":"20","author":"Kiyoi T.","year":"2010","unstructured":"Kiyoi T.; York M.; Francis S.; Edwards D.; Walker G.; Houghton A.K.; Cottney J.E.; Baker J.; Adam J.M.; Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists. Bioorg Med Chem Lett 2010,20(16),4918-4921","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.1016\/j.bmcl.2011.09.083","volume":"21","author":"Chowdhury S.","year":"2011","unstructured":"Chowdhury S.; Sessions E.H.; Pocas J.R.; Grant W.; Schr\u00f6ter T.; Lin L.; Ruiz C.; Cameron M.D.; Sch\u00fcrer S.; LoGrasso P.; Bannister T.D.; Feng Y.; Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). Bioorg Med Chem Lett 2011,21(23),7107-7112","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1016\/j.bmcl.2011.09.084","volume":"21","author":"Sessions E.H.","year":"2011","unstructured":"Sessions E.H.; Chowdhury S.; Yin Y.; Pocas J.R.; Grant W.; Schr\u00f6ter T.; Lin L.; Ruiz C.; Cameron M.D.; LoGrasso P.; Bannister T.D.; Feng Y.; Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II). Bioorg Med Chem Lett 2011,21(23),7113-7118","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.bmcl.2011.01.039","volume":"21","author":"Fang X.","year":"2011","unstructured":"Fang X.; Chen Y.T.; Sessions E.H.; Chowdhury S.; Vojkovsky T.; Yin Y.; Pocas J.R.; Grant W.; Schr\u00f6ter T.; Lin L.; Ruiz C.; Cameron M.D.; LoGrasso P.; Bannister T.D.; Feng Y.; Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors. Bioorg Med Chem Lett 2011,21(6),1844-1848","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.bmcl.2013.01.109","volume":"23","author":"Chowdhury S.","year":"2013","unstructured":"Chowdhury S.; Chen Y.T.; Fang X.; Grant W.; Pocas J.; Cameron M.D.; Ruiz C.; Lin L.; Park H.; Schr\u00f6ter T.; Bannister T.D.; Lograsso P.V.; Feng Y.; Amino acid derived quinazolines as Rock\/PKA inhibitors. Bioorg Med Chem Lett 2013,23(6),1592-1599","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bmcl.2009.12.012","volume":"20","author":"Henderson A.J.","year":"2010","unstructured":"Henderson A.J.; Hadden M.; Guo C.; Douglas N.; Decornez H.; Hellberg M.R.; Rusinko A.; McLaughlin M.; Sharif N.; Drace C.; Patil R.; 2,3-Diaminopyrazines as Rho kinase inhibitors. Bioorg Med Chem Lett 2010,20(3),1137-1140","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1016\/j.bmcl.2010.04.020","volume":"20","author":"Davis R.L.","year":"2010","unstructured":"Davis R.L.; Kahraman M.; Prins T.J.; Beaver Y.; Cook T.G.; Cramp J.; Cayanan C.S.; Gardiner E.M.; McLaughlin M.A.; Clark A.F.; Hellberg M.R.; Shiau A.K.; Noble S.A.; Borchardt A.J.; Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma. Bioorg Med Chem Lett 2010,20(11),3361-3366","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1021\/jm100579r","volume":"53","author":"Fang X.","year":"2010","unstructured":"Fang X.; Yin Y.; Chen Y.T.; Yao L.; Wang B.; Cameron M.D.; Lin L.; Khan S.; Ruiz C.; Schr\u00f6ter T.; Grant W.; Weiser A.; Pocas J.; Pachori A.; Sch\u00fcrer S.; Lograsso P.; Feng Y.; Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem 2010,53(15),5727-5737","journal-title":"J Med Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1021\/acs.jmedchem.5b00424","volume":"58","author":"Green J.","year":"2015","unstructured":"Green J.; Cao J.; Bandarage U.K.; Gao H.; Court J.; Marhefka C.; Jacobs M.; Taslimi P.; Newsome D.; Nakayama T.; Shah S.; Rodems S.; Design, synthesis, and structure-activity relationships of pyridine-based Rho kinase (ROCK) inhibitors. J Med Chem 2015,58(12),5028-5037","journal-title":"J Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1021\/ml1000382","volume":"1","author":"Yin Y.","year":"2010","unstructured":"Yin Y.; Cameron M.D.; Lin L.; Khan S.; Schr\u00f6ter T.; Grant W.; Pocas J.; Chen Y.T.; Sch\u00fcrer S.; Pachori A.; LoGrasso P.; Feng Y.; Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats. ACS Med Chem Lett 2010,1(4),175-179","journal-title":"ACS Med Chem Lett"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1021\/jm400062r","volume":"56","author":"Yin Y.","year":"2013","unstructured":"Yin Y.; Lin L.; Ruiz C.; Khan S.; Cameron M.D.; Grant W.; Pocas J.; Eid N.; Park H.; Schr\u00f6ter T.; Lograsso P.V.; Feng Y.; Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. J Med Chem 2013,56(9),3568-3581","journal-title":"J Med Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"361","DOI":"10.9734\/OR\/2014\/10573","volume":"2","author":"Vohra V.","year":"2014","unstructured":"Vohra V.; Chawla H.; Gupta M.; ROCK Inhibitors: Future of anti-glaucoma medication. Ophthalmol Res Int J 2014,2,361-367","journal-title":"Ophthalmol Res Int J"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/14656566.2017.1378344","volume":"18","author":"Inoue T.","year":"2017","unstructured":"Inoue T.; Tanihara H.; Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opin Pharmacother 2017,18(15),1669-1673","journal-title":"Expert Opin Pharmacother"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1167\/iovs.13-13157","volume":"55","author":"Van de Velde S.","year":"2014","unstructured":"Van de Velde S.; Van Bergen T.; Sijnave D.; Hollanders K.; Castermans K.; Defert O.; Leysen D.; Vandewalle E.; Moons L.; Stalmans I.; AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci 2014,55(2),1006-1016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2174\/09298665113209990057","volume":"13","author":"Abbhi V.","year":"2016","unstructured":"Abbhi V.; Piplani P.; Rho Kinase inhibitors and novel ocular drug delivery systems- a revolutionary step towards the treatment of glaucoma. Curr Drug Deliv 2016,13(6),818-829","journal-title":"Curr Drug Deliv"},{"key":"ref=156","unstructured":"Yale J Biol Med, 90 Amakem Begins Phase II Trial for Locally-Acting ROCK Inhibitor AMA0076 to Treat Glaucoma(Accessed: April 28, 2015).","journal-title":"Yale J Biol Med, 90"},{"key":"ref=157","first-page":"111","volume":"90","author":"Lu L.J.","year":"2017","unstructured":"Lu L.J.; Tsai J.C.; Liu J.; Novel pharmacologic candidates for treatment of primary open-angle glaucoma. Yale J Biol Med 2017,90(1),111-118","journal-title":"Yale J Biol Med"},{"key":"ref=158","unstructured":"Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals Available at:(Accessed: April 29, 2015).","journal-title":"Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals"},{"key":"ref=159","first-page":"754","volume":"54","author":"Weiss M.","year":"2013","unstructured":"Weiss M.; Levy B.; Kopczynski C.; Haarlem T.V.; Novack G.; Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2013,54,754","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","volume":"122","author":"Bacharach J.","year":"2015","unstructured":"Bacharach J.; Dubiner H.B.; Levy B.; Kopczynski C.C.; Novack G.D.; Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology AR-13324-CS202 Study Group2015,122(2),302-307","journal-title":"Ophthalmology"},{"key":"ref=161","unstructured":"Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension Available at:(Accessed: May 1, 2015).","journal-title":"Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension"},{"key":"ref=162","unstructured":"Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals Aerie Reaffirms Timeline to Commence Two Phase 3 Studies By Mid- 2014 Available at:(Accessed: May 3, 2015).","journal-title":"Aerie Pharmaceuticals Reports Positive Results for Lead Candidate AR-13324 in Normotensive Individuals Aerie Reaffirms Timeline to Commence Two Phase 3 Studies By Mid- 2014"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.2013.0197","volume":"30","author":"Kopczynski C.C.","year":"2014","unstructured":"Kopczynski C.C.; Epstein D.L.; Emerging trabecular outflow drugs. J Ocul Pharmacol Ther 2014,30(2-3),85-87","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3892\/or.2012.2205","volume":"29","author":"Yang Z.","year":"2013","unstructured":"Yang Z.; Wang J.; Liu X.; Cheng Y.; Deng L.; Zhong Y.; Y-39983 downregulates RhoA\/Rho-associated kinase expression during its promotion of axonal regeneration. Oncol Rep 2013,29(3),1140-1146","journal-title":"Oncol Rep"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/OPTH.S15971","volume":"5","author":"Chen J.","year":"2011","unstructured":"Chen J.; Runyan S.A.; Robinson M.R.; Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011,5,667-677","journal-title":"Clin Ophthalmol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1111\/bph.12658","volume":"171","author":"Biro M.","year":"2014","unstructured":"Biro M.; Munoz M.A.; Weninger W.; Targeting Rho-GTPases in immune cell migration and inflammation. Br J Pharmacol 2014,171(24),5491-5506","journal-title":"Br J Pharmacol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/eye.2011.82","volume":"25","author":"Lavik E.","year":"2011","unstructured":"Lavik E.; Kuehn M.H.; Kwon Y.H.; Novel drug delivery systems for glaucoma. Eye (Lond) 2011,25(5),578-586","journal-title":"Eye (Lond)"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:39:55Z","timestamp":1775255995000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166780\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":167,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,4,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666181031102829","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}